Production of human cardiomyocytes based on a scalable stem cell culture platform

Cardiovascular diseases are serious and have become the main cause of death worldwide. Cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hiPSCs) have been widely used in cardiovascular disease modeling, heart development research, drug screening and potential cell therapy. Efficient production of CMs from hiPSCs is crucial for its’ basic research and clinical translation. The three-dimensional (3D) suspension culture system is preferred in CMs culture, as it can achieve large-scale production and obtain more mature phenotype, but a robust stem cell culture platform remains unsolved. We previously established a scalable PSC culture platform (termed AIC) that supports PSC passaging at the single-cell level under 3D suspension conditions. However, the efficiency of hiPSCs derived from the AIC system directed differentiation into CMs remains unclear. The research aims to explore the differentiation efficiency of hiPSCs derived from the AIC system.